Online citations, reference lists, and bibliographies.
← Back to Search

Esophagitis Associated With The Use Of Alendronate.

P. de Groen, D. Lubbe, L. Hirsch, A. Daifotis, W. Stephenson, D. Freedholm, S. Pryor-Tillotson, M. Seleznick, H. Pinkas, K. Wang
Published 1996 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND Alendronate, an aminobisphosphonate and a selective inhibitor of osteoclast-mediated bone resorption, is used to treat osteoporosis in postmenopausal women and Paget's disease of bone. Aminobiphosphonates can irritate the upper gastrointestinal mucosa. METHODS We describe three patients who had severe esophagitis shortly after starting to take alendronate and also analyze adverse esophageal effects reported to Merck, the manufacturer, through postmarketing surveillance. RESULTS As of March 5, 1996, alendronate had been prescribed for an estimated 475,000 patients worldwide, and 1213 reports of adverse effects had been received. A total of 199 patients had adverse effects related to the esophagus; in 51 of these patients (26 percent), including the 3 we describe in case reports, adverse effects were categorized as serious or severe. Thirty-two patients (16 percent) were hospitalized, and two were temporarily disabled. Endoscopic findings generally indicated chemical esophagitis, with erosions or ulcerations and exudative inflammation accompanied by thickening of the esophageal wall. Bleeding was rare, and stomach or duodenal involvement unusual. In patients for whom adequate information was available, esophagitis seemed to be associated with swallowing alendronate with little or no water, lying down during or after ingestion of the tablet, lying down during or after ingestion of the tablet, continuing to take alendronate after the onset of symptoms, and having preexisting esophageal disorders. CONCLUSIONS Alendronate can cause chemical esophagitis, including severe ulcerations, in some patients. Recommendations to reduce the risk of esophagitis include swallowing alendronate with 180 to 240 ml (6 to 8 oz) of water on arising in the morning, remaining upright for at least 30 minutes after swallowing the tablet and until the first food of the day has been ingested, and discontinuing the drug promptly if esophageal symptoms develop.
This paper references
10.1007/BF03273413
Monitoring for drug safety
W. Inman (1981)
10.1136/bmj.285.6356.1717
Oesophageal transit of six commonly used tablets and capsules.
H. Hey (1982)
10.1002/JPS.2600720917
Effect of dosage form and formulation factors on the adherence of drugs to the esophagus.
M. Marvola (1983)
10.1002/j.1552-4604.1986.tb02922.x
The Effect of Size and Shape of Tablets on Their Esophageal Transit
K. Channer (1986)
10.1016/8756-3282(94)90818-4
Effects of two oral doses of alendronate in the treatment of Paget's disease of bone.
S. Adami (1994)
10.1056/NEJM199511303332201
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
U. Liberman (1995)
10.1016/S8756-3282(95)00262-6
Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
S. Adami (1995)
Multiple ulcerative esophagitis caused by alendronate.
G. Maconi (1995)
10.1016/S0002-9343(99)80134-X
Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.
C. Chesnut (1995)
10.1016/0009-9236(95)90245-7
Studies of the oral bioavailability of alendronate
B. Gertz (1995)
10.2165/00002018-199614030-00003
Adverse Effects of Bisphosphonates
S. Adami (1996)
10.1056/NEJM199610033351416
Esophagitis and alendronate.
U. Liberman (1996)
10.1210/JC.81.3.961
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone.
E. Siris (1996)



This paper is referenced by
10.1097/MD.0000000000022839
Bisphosphonates and risk of lung cancer
Minghao Li (2021)
10.1007/s11864-021-00835-2
Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy
A. Diana (2021)
10.1016/j.cger.2020.09.001
Upper Gastrointestinal Bleeding.
N. Costable (2021)
10.1002/ygh2.400
Bisphosphonates and risk of oesophageal cancer: A meta‐analysis
Ming-hao Li (2020)
10.1016/j.heliyon.2020.e04321
Dentists' knowledge about medication-related osteonecrosis of the jaw and its management
R. Al-Eid (2020)
10.21518/2079-701X-2020-7-122-128
ПЕРОРАЛЬНЫЕ БИСФОСФОНАТЫ КАК ТЕРАПИЯ ВЫБОРА У ПАЦИЕНТОВ С УМЕРЕННЫМ РИСКОМ ПЕРЕЛОМОВ
Лариса Александровна Марченкова (2020)
10.3389/fendo.2020.573976
Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials
Z. Dömötör (2020)
10.1016/j.pharmthera.2020.107611
New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma.
K. Lu (2020)
10.1038/s41598-020-68037-8
Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis
Yeesuk Kim (2020)
10.1002/14651858.cd013424
Pharmacological interventions for osteoporosis in people with chronic kidney disease stages 3‐5D
T. Hara (2019)
10.1016/b978-0-323-37755-3.50061-1
Drug Induced Esophagitis
F. Saleem (2019)
10.21518/2079-701X-2019-18-119-126
Боль в спине и остеопороз позвоночника в клинической практике
Наталия Вячеславовна Пизова (2019)
10.14670/HH-18-161
Alendronate effect in esophagus, stomach and liver: an animal based pathological study.
T. Papamitsou (2019)
10.12968/DENU.2018.45.1.38
Oral Mucosal Ulceration Induced by Alendronic Acid: A Case Series
D. Finn (2018)
10.1016/B978-0-12-801238-3.95672-1
Pathologic Response of the Gastrointestinal Tract to Toxicants
A. McCarthy (2018)
10.1016/j.addr.2018.09.003
Challenges and innovations of drug delivery in older age
M. S. Khan (2018)
10.1016/B978-0-12-801238-3.64315-5
Clinical Toxicity: Esophagus
Aoife J McCarthy (2018)
10.1016/j.legalmed.2017.11.003
Highly sensitive determination of alendronate in human plasma and dialysate using metal-free HPLC-MS/MS.
Miho Yamada (2018)
10.1016/j.ijom.2017.04.014
Does local delivery of bisphosphonates influence the osseointegration of titanium implants? A systematic review.
M. B. Guimarães (2017)
Upper Gastrointestinal Tract Safety Profile of Alendronate
D. Bauer (2017)
10.1016/j.path.2017.07.007
The Many Faces of Medication-Related Injury in the Gastrointestinal Tract.
H. Kwak (2017)
10.12968/GASN.2017.15.8.26
Primary sclerosing cholangitis: a pre-malignant condition
G. Mortimore (2017)
10.1007/978-1-4939-7012-4_14
In Vivo Characterization of Oral Multiparticulate Systems
L. Hodges (2017)
10.3748/wjg.v22.i3.906
Bisphosphonates as potential adjuvants for patients with cancers of the digestive system.
C. Ang (2016)
10.1021/ACS.CGD.6B01064
Solid-State Phase Transition Mechanism and Physical–Chemical Study of the Crystal Forms of Monosodium Alendronate: Trihydrate versus Anhydrate
Edeilson V. Gonzaga (2016)
10.1016/J.APSUSC.2016.01.184
Risedronate adsorption on bioactive glass surface for applications as bone biomaterial
S. Mosbahi (2016)
10.1016/j.jcms.2015.03.014
The influence of geranylgeraniol on human oral keratinocytes after bisphosphonate treatment: An in vitro study.
A. Pabst (2015)
10.1016/j.ijbiomac.2014.10.064
Kinetic release studies of nitrogen-containing bisphosphonate from gum acacia crosslinked hydrogels.
B. Aderibigbe (2015)
10.1002/9781118655153.CH1
Epidemiology of esophageal carcinoma
Mohammad H. Shakhatreh (2015)
Role of Osteoclasts in the potential pathogenic mechanism of Osteonecrosis of Jaw
L. Angeles (2015)
10.1016/j.ijom.2015.05.013
Influence of the local application of sodium alendronate gel on osseointegration of titanium implants.
Magáli Beck Guimarães (2015)
10.1371/journal.pone.0128110
Histomorphological and Immunophenotypic Features of Pill-Induced Esophagitis
J. Kim (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar